Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 or QL1604 plus bevacizumab in advanced hepatocellular carcinoma
CTR20211837Phase 2Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of QL1706, iparomlimab, bevacizumab in hepatocellular carcinoma (HCC), sponsored by Qilu Pharmaceutical. Started Aug 2021; status: completed.
02
Drugs
QL1706iparomlimabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20211837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211837.